Shashikala Venkatachalapathy, MD
Psychiatry · Salisbury, MDNPI 1669555462
Payments from drug & device makers
Across 565 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- AbbVie$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$913
- Lundbeck LLC$853
- Otsuka America Pharmaceutical, Inc.$814
- plus $5K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 106 | $1,352 |
| AbbVie(2 entities) | 77 | $1,281 |
| Alkermes, Inc. | 41 | $1,046 |
| Teva Pharmaceuticals USA, Inc. | 40 | $913 |
| Lundbeck LLC | 48 | $853 |
| Otsuka America Pharmaceutical, Inc. | 40 | $814 |
| Vanda Pharmaceuticals Inc. | 23 | $708 |
| Sunovion Pharmaceuticals Inc. | 29 | $659 |
| Johnson & Johnson | 30 | $618 |
| E.r. Squibb & Sons, L.L.C. | 18 | $567 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $477 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $463 |
| Axsome Therapeutics, Inc. | 12 | $373 |
| Indivior Inc. | 11 | $200 |
| Idorsia Pharmaceuticals US Inc | 8 | $180 |
| Exact Sciences | 7 | $154 |
| Boehringer Ingelheim | 1 | $111 |
| Eisai Inc. | 5 | $93 |
| Novo Nordisk | 4 | $73 |
| Abbott | 2 | $41 |
| Pfizer | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $33 |
| Neuronetics, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Vertos Medical, Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Tempus AI, Inc | 1 | $14 |
| Vistapharm, Inc. | 1 | $14 |
How this compares
$11,160 in reported general payments places this provider in the 90th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Salisbury
- Elia Acevedo DiazGaithersburg$15.8M
- Akira SawaBaltimore$5.1M
- John VaethBaltimore$2.1M
- Paul RosenbergBaltimore$1.9M
- Scott AaronsonBaltimore$1.3M
- Karen AndersonBaltimore$1.1M
- Constantine LyketsosBaltimore$1.1M
- Alan JonasBaltimore$1.1M
- Sarah HertsBaltimore$1M
- Robert LehmanBaltimore$947K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.